Addressing The Overlooked AMR Problem w/ Dr. Henry Skinner
Investors are logical people. They invest in medicines that they expect will give them a return.
Right now, there’s far too little investment in developing new antibiotics. The pipeline of treatment is thin, but the need is greater than ever.
Enter the AMR Action Fund.
Hear our conversation with Dr. Henry Skinner, Chief Executive Officer at AMR Action Fund about:
The increasing cost of AMR and policy challenges
How to build the pipeline to reach the new antibiotics we need to save millions
Leveraging healthcare innovation for AMR before it’s too late
AMR Action Fund’s first two investments…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.